Kailera Therapeutics, Inc.
Ownership
Ownership Structure
Who owns Kailera Therapeutics, Inc. (KLRA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 45.1% of the shares are freely tradable; institutional investors hold 51.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Bain Capital Investors LLC | 20.25 | 26,255,581 | +0.0 | 06/30/2026 |
| Canada Pension Plan Investment Board | 5.63 | 7,304,688 | +0.0 | 06/30/2026 |
| Atlas Venture Life Science Advisors, LLC | 3.99 | 5,171,282 | +0.0 | 06/30/2026 |
| Citadel Advisors Llc | 2.50 | 3,240,787 | +0.0 | 06/30/2026 |
| Adage Capital Partners Gp LLC | 2.47 | 3,208,286 | +0.0 | 06/30/2026 |
| Wellington Management Company LLP | 2.25 | 2,919,110 | +0.0 | 06/30/2026 |
| Royalty Pharma Sub-Manager, LLC | 1.89 | 2,455,357 | +0.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Health Care Inv | 1.69 | 2,191,928 | +0.0 | 06/30/2026 |
| T. Rowe Price Health Sciences | 1.18 | 1,530,986 | +0.0 | 07/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 0.91 | 1,180,411 | +0.0 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | Adam Koppel | Director | Buy | 1,562,500 | 16.00 | 25,000,000 |
| Apr 20, 2026 | Andrew T Kaplan | Director | Buy | 8,398,438 | 16.00 | 134,375,008 |
| Apr 20, 2026 | Rtw Investments, Lp | Major Shareholder | Buy | 500,000 | 16.00 | 8,000,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.